FAQs

There have been some reports of hair loss, known as alopecia, in people taking Sinemet. Weight gain also has been reported with the use of levodopa alone and with various carbidopa and levodopa formulations; this side effect may occur with Sinemet.

Sinemet reaches a peak concentration in the blood about half an hour after administration, at which point an easing in Parkinson’s symptoms should already be evident. However, because the initial recommended dose of Sinemet must be carefully determined for each patient, some individuals may require dose adjustments before experiencing…

Some patients on Sinemet have reported somnolence, or sleepiness, and suddenly falling asleep without warning during daily activities. Thus, until patients know exactly how the therapy affects them, those initiating treatment should not drive and should avoid other potentially dangerous activities that might result in harm if they become somnolent.

Animal studies suggest that Sinemet may cause harm to a developing fetus. However, the therapy has not been well studied in pregnant women so it should be used during pregnancy only if the potential benefit justifies the potential risk to the mother and child. Patients who become or intend to…

The U.S. Food and Drug Administration approved Sinemet in 1975 for the treatment of people with Parkinson’s disease, to ease symptoms of the neurodegenerative disorder. This marked the first approval in the U.S. of a combination therapy containing both levodopa and carbidopa. The regulatory agency also approved the…

In Kynmobi clinical trials, there were no reports of hair loss or weight gain related to the therapy. However, because the medication may cause impulse control disorders, including compulsive eating, some patients may experience weight gain while taking Kynmobi. Patients should talk with their healthcare team if they experience any…

In the trials that supported Kynmobi’s approval, patients on the therapy showed a significant reduction in motor impairment during off periods as early as 15 minutes post-dosing, with the greatest effects seen after one hour. However, as each patient is unique and may respond differently to a given treatment, a…

Because some people on Kynmobi may experience sleepiness or fall asleep during daily activities, patients starting treatment are recommended to avoid driving or other potentially dangerous activities until they know how the medication affects them. If patients do experience such adverse events, they are advised to avoid any type of…

Animal studies suggest Kynmobi may cause fetal harm, but there are no clinical data on the therapy’s effects on pregnant or breastfeeding patients. Thus, it is unclear whether the use of Kynmobi is safe in such conditions. Patients who are pregnant or plan to become pregnant should discuss this issue…

The U.S. Food and Drug Administration (FDA) approved Kynmobi in May 2020 for the treatment of short-term, intermittent off episodes in people with Parkinson’s disease. This made Kynmobi the first under-the-tongue or sublingual treatment for Parkinson’s off episodes to be approved in the U.S.